Real-World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis
Issued Date
2024-11-01
Resource Type
ISSN
17502640
eISSN
17502659
Scopus ID
2-s2.0-85208262100
Journal Title
Influenza and other Respiratory Viruses
Volume
18
Issue
11
Rights Holder(s)
SCOPUS
Bibliographic Citation
Influenza and other Respiratory Viruses Vol.18 No.11 (2024)
Suggested Citation
Khaing W., Tan C., Patikorn C., Techasaensiri C., Pattanaprateep O., Dhippayom T., Bruminhent J., Chaiyakunapruk N. Real-World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis. Influenza and other Respiratory Viruses Vol.18 No.11 (2024). doi:10.1111/irv.70039 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/101985
Title
Real-World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections worldwide, including Thailand. This study aimed to assess clinical and economic burdens of RSV infections across different age groups in Thailand. Method: A retrospective cohort study was conducted using data from a tertiary care hospital from 2014 to 2021. Patients who tested at least one positive RSV were included and stratified into five age groups (< 2, 2–5, 5–18, 18–65, and > 65 years). Healthcare resource utilization, direct medical costs, and clinical outcomes were analyzed with descriptive statistics. Generalized linear models with gamma distributions and log link were used to model cost outcomes. Costs were reported in 2021 US dollars (USD), with 1 USD = 31.98 Thai Baht. Results: A total of 2122 RSV-positive patients were identified, half of which (1097) were hospitalized. The median (interquartile range [IQR]) total hospitalization costs ranged from USD780 (IQR: USD488–USD1185) in those < 2 years to USD2231 (IQR: USD1250–USD4989) in those aged 65+ years. Case fatality rates among hospitalized patients also varied from 2.5% to 28.4% depending on age. Increased age, presence of comorbidities, and need for critical care were associated with higher hospitalization costs. Conclusion: Among RSV-positive patients, younger children experienced the greatest burden, but poorer outcomes were observed in older adults. Higher costs were associated with older age, comorbidities and critical care needs. Understanding RSV economic burdens is crucial for assessing the cost-effectiveness and public health value of vaccination programs that prioritize at-risk groups to mitigate the public health impact.